Grace P Tamesis1, Ronina A Covar. 1. Department of Pediatrics, National Jewish Medical and Research Center, 1400 Jackson Street, Denver, CO 80206, USA.
Abstract
PURPOSE OF REVIEW: This review describes recent studies in children that evaluated long-term outcomes of controller asthma medications. RECENT FINDINGS: The literature is replete with studies demonstrating the immediate profound effects of inhaled corticosteroids on symptom control, reduction in morbidity and mortality rates, improvement in lung function, bronchial hyperresponsiveness, and inflammatory markers. Recent evidence supports that even this most effective class of medication does not alter the progression of recurrent wheeze to asthma, and that its effects on decline in lung function are limited. The lack of evidence supporting the superiority of lower dose inhaled corticosteroids combined with a long-acting beta-agonist over a full dose inhaled corticosteroid with respect to long-term efficacy measures and growth effects suggests that monotherapy with acceptable inhaled corticosteroid dose is the preferred treatment in children with mild to moderate persistent asthma. Montelukast has been shown to significantly reduce asthma exacerbations and lower use of supplemental inhaled corticosteroids compared with placebo. SUMMARY: There is mounting evidence that the currently available medications for childhood asthma have a substantial impact on multiple dimensions of asthma control. No drug in our current armamentarium, however, has been found to alter the natural progression of childhood asthma nor halt progressive airway damage in the more susceptible children.
PURPOSE OF REVIEW: This review describes recent studies in children that evaluated long-term outcomes of controller asthma medications. RECENT FINDINGS: The literature is replete with studies demonstrating the immediate profound effects of inhaled corticosteroids on symptom control, reduction in morbidity and mortality rates, improvement in lung function, bronchial hyperresponsiveness, and inflammatory markers. Recent evidence supports that even this most effective class of medication does not alter the progression of recurrent wheeze to asthma, and that its effects on decline in lung function are limited. The lack of evidence supporting the superiority of lower dose inhaled corticosteroids combined with a long-acting beta-agonist over a full dose inhaled corticosteroid with respect to long-term efficacy measures and growth effects suggests that monotherapy with acceptable inhaled corticosteroid dose is the preferred treatment in children with mild to moderate persistent asthma. Montelukast has been shown to significantly reduce asthma exacerbations and lower use of supplemental inhaled corticosteroids compared with placebo. SUMMARY: There is mounting evidence that the currently available medications for childhood asthma have a substantial impact on multiple dimensions of asthma control. No drug in our current armamentarium, however, has been found to alter the natural progression of childhood asthma nor halt progressive airway damage in the more susceptible children.
Authors: K Takeda; Y Shiraishi; S Matsubara; N Miyahara; H Matsuda; M Okamoto; A Joetham; E W Gelfand Journal: Br J Pharmacol Date: 2010-07 Impact factor: 8.739
Authors: Carolin Veit; Ronald Herrera; Gudrun Weinmayr; Jon Genuneit; Doris Windstetter; Christian Vogelberg; Erika von Mutius; Dennis Nowak; Katja Radon; Jessica Gerlich; Tobias Weinmann Journal: BMC Med Res Methodol Date: 2020-12-16 Impact factor: 4.615